460 related articles for article (PubMed ID: 33770334)
1. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals.
Mistler CB; Curley CM; Rosen AO; El-Krab R; Wickersham JA; Copenhaver MM; Khati A; Shrestha R
J Community Health; 2021 Oct; 46(5):960-966. PubMed ID: 33770334
[TBL] [Abstract][Full Text] [Related]
2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
[TBL] [Abstract][Full Text] [Related]
3. Missed opportunities for healthcare providers to discuss HIV preexposure prophylaxis with people who inject drugs.
Vincent W; McFarland W
Int J Drug Policy; 2022 Dec; 110():103873. PubMed ID: 36252292
[TBL] [Abstract][Full Text] [Related]
4. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
[TBL] [Abstract][Full Text] [Related]
5. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
[TBL] [Abstract][Full Text] [Related]
6. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
[TBL] [Abstract][Full Text] [Related]
7. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
[TBL] [Abstract][Full Text] [Related]
8. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
[TBL] [Abstract][Full Text] [Related]
9. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
[TBL] [Abstract][Full Text] [Related]
10. HIV Exposure Prophylaxis Delivery in a Low-barrier Substance Use Disorder Bridge Clinic during a Local HIV Outbreak at the Onset of the COVID-19 Pandemic.
Braun HM; Walter C; Farrell N; Biello KB; Taylor JL
J Addict Med; 2022 Nov-Dec 01; 16(6):678-683. PubMed ID: 36383918
[TBL] [Abstract][Full Text] [Related]
11. Continuing Low Awareness and Use of Pre-exposure Prophylaxis (PrEP) for HIV among People Who Inject Drugs (PWID), San Francisco, 2022.
Suprasert B; Tate M; Reagan D; Ruiz R; Gao K; McNaughton K; Miller K; Marr A; Taylor KD; Wilson EC; McFarland W
AIDS Behav; 2024 Jun; 28(6):2089-2100. PubMed ID: 38526638
[TBL] [Abstract][Full Text] [Related]
12. PrEP Use and Persistence Among Young Sexual Minority Men 17-24 Years Old During the COVID-19 Pandemic.
Hong C; Horvath KJ; Stephenson R; Nelson KM; Petroll AE; Walsh JL; John SA
AIDS Behav; 2022 Mar; 26(3):631-638. PubMed ID: 34387777
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
14. Low PrEP Awareness and Use Among People Who Inject Drugs, San Francisco, 2018.
McFarland W; Lin J; Santos GM; Arayasirikul S; Raymond HF; Wilson E
AIDS Behav; 2020 May; 24(5):1290-1293. PubMed ID: 31563984
[TBL] [Abstract][Full Text] [Related]
15. "Maintaining HIV and HCV prevention and care for people who inject drugs despite COVID-19 in Hai Phong, Vietnam".
Giang HT; Duc NQ; Molès JP; Vinh VH; Nagot N; Thanh NTT; Huong DT; Oanh KTH; Khue PM; Mai LS; Trang NT; Ngoc PT; Quillet C; Feelemyer J; Vallo R; Michel L; Jarlais DD; Laureillard D; Rapoud D
Int J Drug Policy; 2022 Dec; 110():103870. PubMed ID: 36244242
[TBL] [Abstract][Full Text] [Related]
16. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
[TBL] [Abstract][Full Text] [Related]
17. HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: Results from a prospective observational study in Germany.
Uhrmacher M; Skaletz-Rorowski A; Nambiar S; Schmidt AJ; Ahaus P; Serova K; Mordhorst I; Kayser A; Wach J; Tiemann C; Münstermann D; Brockmeyer NH; Potthoff A
Front Public Health; 2022; 10():930208. PubMed ID: 36091531
[TBL] [Abstract][Full Text] [Related]
18. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
[TBL] [Abstract][Full Text] [Related]
20. Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study.
Allen ST; O'Rourke A; White RH; Smith KC; Weir B; Lucas GM; Sherman SG; Grieb SM
AIDS Behav; 2020 Jun; 24(6):1942-1950. PubMed ID: 31853771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
